CAR T-cell therapy modifies a patient's T cells in a laboratory and returns them by infusion. It is not a universal cancer treatment, and a single success rate cannot predict an individual outcome. Eligibility depends on cancer type, previous treatment, health status, product and centre capability.
Confirm the indication
Current CAR T-cell therapies are used mainly for certain blood cancers; other uses may remain under study. Assessment must be performed by a qualified haematology or oncology team, with the product's local approval status checked.
Understand the complete process
The pathway may include record review, T-cell collection, manufacturing, a waiting period, conditioning treatment, infusion and close monitoring. Manufacturing and bridging treatment vary, so a website cannot promise fixed dates.
Discuss serious risks
Cytokine release syndrome, neurological toxicity, infection and low blood counts can be severe or life-threatening. Ask about monitoring, emergency capability and warning signs after discharge.
Plan cross-border continuity
Confirm fitness to travel, companion requirements, distance from the centre, long-term follow-up, vaccination and infection precautions, and who will continue care at home. Costs and insurance require case-specific written confirmation.
Questions for the treatment centre
- Indication and alternatives
- Product approval or research status
- Plan during manufacturing
- Management of serious adverse events
- Long-term and home-country follow-up
Primary sources
Sources were checked on the review date shown above.